PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1460.0
(-2.67%)
IDR 1460.0
(-2.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 190.05 Billion IDR | -9.08% |
| 2022 | 198.34 Billion IDR | -4.92% |
| 2021 | 208.6 Billion IDR | -1.0% |
| 2020 | 210.71 Billion IDR | -28.96% |
| 2019 | 296.62 Billion IDR | 10.97% |
| 2018 | 267.3 Billion IDR | 21.52% |
| 2017 | 219.96 Billion IDR | 8.02% |
| 2016 | 203.63 Billion IDR | 60.67% |
| 2015 | 126.73 Billion IDR | 34.16% |
| 2014 | 94.47 Billion IDR | -43.46% |
| 2013 | 167.07 Billion IDR | -14.83% |
| 2012 | 196.16 Billion IDR | 22.47% |
| 2011 | 160.17 Billion IDR | 16.84% |
| 2010 | 137.08 Billion IDR | 14.88% |
| 2009 | 119.32 Billion IDR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 90.86 Billion IDR | 9.76% |
| 2024 Q3 | 39.61 Billion IDR | -38.3% |
| 2024 Q2 | 64.19 Billion IDR | -29.35% |
| 2023 Q4 | 82.78 Billion IDR | 1899.12% |
| 2023 FY | 180.33 Billion IDR | -9.08% |
| 2023 Q1 | 79 Billion IDR | 110.47% |
| 2023 Q2 | 46.53 Billion IDR | -41.1% |
| 2023 Q3 | 4.14 Billion IDR | -91.1% |
| 2022 Q4 | -754.67 Billion IDR | -4330.65% |
| 2022 Q1 | 176.65 Billion IDR | 231.04% |
| 2022 Q2 | 41.48 Billion IDR | -76.52% |
| 2022 FY | 198.34 Billion IDR | -4.92% |
| 2022 Q3 | -17.03 Billion IDR | -141.06% |
| 2021 Q4 | -134.8 Billion IDR | -177.78% |
| 2021 FY | 208.6 Billion IDR | -1.0% |
| 2021 Q1 | 107.88 Billion IDR | 407.38% |
| 2021 Q2 | 62.2 Billion IDR | -42.34% |
| 2021 Q3 | 173.31 Billion IDR | 178.61% |
| 2020 Q1 | 74.31 Billion IDR | 24.35% |
| 2020 Q4 | 21.26 Billion IDR | 71.95% |
| 2020 Q3 | 12.36 Billion IDR | -87.97% |
| 2020 FY | 210.71 Billion IDR | -28.96% |
| 2020 Q2 | 102.77 Billion IDR | 38.29% |
| 2019 Q3 | 85.48 Billion IDR | 109.82% |
| 2019 Q1 | 110.63 Billion IDR | 121.68% |
| 2019 Q2 | 40.74 Billion IDR | -63.18% |
| 2019 FY | 296.62 Billion IDR | 10.97% |
| 2019 Q4 | 59.76 Billion IDR | -30.09% |
| 2018 FY | 267.3 Billion IDR | 21.52% |
| 2018 Q4 | 49.9 Billion IDR | -32.56% |
| 2018 Q3 | 74 Billion IDR | 20.07% |
| 2018 Q2 | 61.63 Billion IDR | -24.62% |
| 2018 Q1 | 81.76 Billion IDR | 1017.92% |
| 2017 Q2 | 53.31 Billion IDR | -49.8% |
| 2017 Q3 | 69.36 Billion IDR | 30.12% |
| 2017 Q1 | 106.19 Billion IDR | 317.15% |
| 2017 FY | 219.96 Billion IDR | 8.02% |
| 2017 Q4 | -8.9 Billion IDR | -112.84% |
| 2016 Q2 | 34.04 Billion IDR | -51.46% |
| 2016 Q4 | 25.45 Billion IDR | -65.6% |
| 2016 FY | 203.63 Billion IDR | 60.67% |
| 2016 Q1 | 70.13 Billion IDR | 798.53% |
| 2016 Q3 | 73.99 Billion IDR | 117.36% |
| 2015 Q3 | 22.44 Billion IDR | 1.84% |
| 2015 FY | 126.73 Billion IDR | 34.16% |
| 2015 Q1 | 74.45 Billion IDR | 986.22% |
| 2015 Q2 | 22.03 Billion IDR | -70.4% |
| 2015 Q4 | 7.8 Billion IDR | -65.22% |
| 2014 Q1 | -20.64 Billion IDR | -149.34% |
| 2014 FY | 94.47 Billion IDR | -43.46% |
| 2014 Q4 | 6.85 Billion IDR | -78.26% |
| 2014 Q3 | 31.53 Billion IDR | -58.9% |
| 2014 Q2 | 76.72 Billion IDR | 471.68% |
| 2013 Q3 | 10.94 Billion IDR | -75.96% |
| 2013 Q1 | 57.76 Billion IDR | 11.92% |
| 2013 FY | 167.07 Billion IDR | -14.83% |
| 2013 Q4 | 41.83 Billion IDR | 282.22% |
| 2013 Q2 | 45.54 Billion IDR | -21.17% |
| 2012 Q3 | 29.69 Billion IDR | 0.0% |
| 2012 FY | 196.16 Billion IDR | 22.47% |
| 2012 Q4 | 51.61 Billion IDR | 73.83% |
| 2011 FY | 160.17 Billion IDR | 16.84% |
| 2010 FY | 137.08 Billion IDR | 14.88% |
| 2009 FY | 119.32 Billion IDR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| PT Merck Tbk | 199.72 Billion IDR | 4.846% |
| PT Phapros, Tbk | 71.32 Billion IDR | -166.472% |
| PT Pyridam Farma Tbk | 1.87 Billion IDR | -10011.78% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 1190.87 Billion IDR | 84.041% |
| PT Tempo Scan Pacific Tbk | 1257.95 Billion IDR | 84.892% |